Shortcut to Body Shortcut to main menu

Invest Korea

Search
Search
※ Click the button below to use Customized Information Search services.
Quick Link to Customized Information Search services

Project

  • Home
  • About us
  • IKMP
  • Project
[Finance]
Anti-cancer drug “CM-7919”
Date : 2022.01.24
• Possessing a source material for arsenic-based anticancer – Chemas has secured the safety of As 4 O 6 (CM-7919), an arsenic compound, by successfully completing the phase 1 clinical trials from 2004 to 2005. Chemas’ phase 2 clinical trials have now been approved by the Ministry of Food and Drug Safety. This material can be used as an anti-cancer agent and COVID-19 cure, since it can be applied to treat the symptoms of a variety of diseases such as solid cancers and blood cancers, such as brain cancer, breast cancer, bladder cancer, liver cancer, pancreatic cancer, uterine cancer, ovarian cancer, lung cancer, and diseases caused by viruses.

• Anti-cancer agent market – According to GBI Research, the anti-cancer agent market is expected to grow rapidly to USD190 billion (about KRW 230 trillion) in 2022, and, in particular, the immune checkpoint inhibitor is expected to occupy 39% of the market at USD75.8 billion (about KRW 90 trillion). Discussion with the global CRO has also been completed, so COVID-19 and anti-cancer clinical trials can be started in Europe right after investment.
  • Investment Requirement
    • Amount : 15M
    • Region : North America , China , Europe , Japan , Southeast Asia , Middle East